Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06866691 · ClinicalTrials.gov registry record · Phase 4
Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide
A Phase 4 study of Traumatic Brain Injury, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 1
- Study location
NCT06866691: Recruiting Phase 4 study of Traumatic Brain Injury, sponsored by Wake Forest University Health Sciences.
NCT06866691 is a Phase 4 study of Traumatic Brain Injury that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 600 participants, above the 274-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (119% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06866691, a Phase 4 study of Traumatic Brain Injury, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with moderate to severe traumatic brain injury requiring seizure prophylaxis.
Primary Outcome
Number of early post-traumatic seizures documented
Conditions Studied
Interventions
- DRUG levetiracetam
- DRUG lacosamide
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-04-18 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What NCT06866691 shows while recruiting
NCT06866691 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 274-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (119% higher).
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which levetiracetam is the first listed.
NCT06866691 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06866691 about?
NCT06866691 is a clinical study titled "Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide". The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with moderate to severe traumatic brain injury requiring seizure pr...
What is the current status of trial NCT06866691?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2025-04-18. Estimated completion is 2027-04.
What conditions does trial NCT06866691 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT06866691?
The interventions under investigation include: levetiracetam (DRUG), lacosamide (DRUG).
Who is sponsoring clinical trial NCT06866691?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06866691 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06866691's enrollment target sits among peer trials
600 11th of 171 higher than 160 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures
RECRUITING · Phase 4
-
tPBM in Older Adults With Traumatic Brain Injury
RECRUITING · NA
-
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
RECRUITING · Phase 1
-
Carbon Dioxide Administration and Brain Waste Clearance
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Cortical Spreading Depolarization After Severe Traumatic Brain Injury
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI